Departament of Pharmacy, Hospital Universitario 12 de Octubre, Madrid, Spain.
Departament of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain.
J Clin Pharm Ther. 2021 Jun;46(3):862-864. doi: 10.1111/jcpt.13357. Epub 2021 Jan 6.
In paediatrics, evidence regarding the treatment of viral myocarditis using interferon beta-1B is restricted to four children older than two years and there are no reported cases of infants. The objective was to describe the efficacy and safety of interferon beta-1B in two infants under one year of age with viral myocarditis.
Two infants were admitted to the hospital presenting with respiratory symptoms. Echocardiogram showed myocardial damage. Parvovirus-B19 was detected using a PCR assay, and treatment with interferon beta-1B was initiated. Six months later, the cardiac function had recovered in both cases.
This is the first published series of cases of infants less than 1 year of age with viral myocarditis treated with interferon beta-1B.
在儿科领域，关于使用干扰素β-1B 治疗病毒性心肌炎的证据仅限于 4 名两岁以上的儿童，且尚无关于婴儿的报告病例。本研究旨在描述干扰素β-1B 在 2 名患有病毒性心肌炎的一岁以下婴儿中的疗效和安全性。
两名婴儿因呼吸症状入院。超声心动图显示心肌损伤。使用 PCR 检测法检测到细小病毒 B19，开始使用干扰素β-1B 进行治疗。6 个月后，两名患儿的心脏功能均已恢复。
这是首例报道使用干扰素β-1B 治疗小于 1 岁的婴儿病毒性心肌炎的病例系列。
